行情

ZGNX

ZGNX

Zogenix
NASDAQ

实时行情|Nasdaq Last Sale

23.05
-0.05
-0.22%
交易中 15:06 04/02 EDT
开盘
23.04
昨收
23.10
最高
23.94
最低
22.67
成交量
34.63万
成交额
--
52周最高
57.22
52周最低
16.65
市值
12.40亿
市盈率(TTM)
-2.3687
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ZGNX价格均价为54.54,最高价位76.00,最低价为25.00。

EPS

ZGNX 新闻

更多
  • Mizuho Maintains Buy on Zogenix, Lowers Price Target to $64
  • Benzinga · 1天前
  • Is Zogenix, Inc. (ZGNX) Going to Burn These Hedge Funds?
  • Insider Monkey · 4天前
  • Edited Transcript of ZGNX earnings conference call or presentation 2-Mar-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 03/24 11:52
  • Co-founder & Chairman Cam Garner Just Bought Shares In Zogenix, Inc. (NASDAQ:ZGNX)
  • Simply Wall St. · 03/21 14:08

所属板块

生物技术和医学研究
+1.59%
制药与医学研究
+1.37%

热门股票

代码
价格
涨跌幅

ZGNX 简况

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.
展开

微牛提供Zogenix, Inc.(NASDAQ-ZGNX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ZGNX股票新闻,以帮助您做出投资决策。